´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2023 Spring Semi-Annual Meeting 1ÀÏÂ÷ : 2023-05-19
±³À°ÀÏÀÚ : 2023-05-19
±³À°Àå¼Ò : ¿©¼ö¾×½ºÆ÷ÄÁº¥¼Ç
±³À°ÁÖÁ¦ : KGOG 2023 Spring Semi-Annual Meeting 1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ : kiskgog@hanmail.net
±³À°Á¾·ù : »êºÎÀΰú, ¹æ»ç¼±Á¾¾çÇаú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 3 ½Ã°£ 56ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:00~13:15 Current status, protocol amendments, and a dummy-run evaluation À§Âù¿ì(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:15~13:30 RT-QA for SABR-ROC ±èÈ£Áø(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:30~13:45 Practical issues of RT simulation and planning ±è¼¼¿µ(¿¬¼¼¾Ïº´¿ø)
Åä·Ð 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 13:45~13:55 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:00~14:05 KGOG1047/Debulk Protocol update ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:10~14:25 E-CRF opening and demonstration ÇÑ°æÈñ(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:25~14:40 Registration Cases and Practical Difficulties ±è´ë¿¬(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:40~14:50 Spatiotemporal genomics in cancer ÀÌÁø±¸(¼¿ïÀÇ´ë)
Åä·Ð 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 14:50~15:00 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:00~15:03 Cervix, Vulva, Vagina Committee-introduction À̱ÙÈ£(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:03~15:13 Review of study of cervical cancer in GOG 2023-NRG winter 2023 Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:13~15:23 Review of study of cervical cancer in GOG 2023-SGO 2023 À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:23~15:38 Brainstorming session 3-1. Clinical trials in preinvasive CIN ±è¹ÎÁ¤(ÀÏ»êÂ÷º´¿ø)
Åä·Ð 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:38~15:43 discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:43~15:58 Brainstorming session 3-1. Clinical trialos in vulva, vagina °øÅ¿í(¾ÆÁִ뺴¿ø)
Åä·Ð 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 15:58~16:01 discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 16:01~16:16 Review of protocol-Debulk, selpax, after ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 17:00~17:15 The Eolution of Endometrial Cancers: Biomarkers and Clinical Decision Making Á¤¹ÎÇü(°æÈñ´ëº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 17:15~17:30 Transforming Outcomes: Endometrial Cancer and Dostarlimab Á¶ÇѺ°(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 17:30~17:45 Impact of MLH1 mutation vs. hypermethylation on response to PD-1 antibody Odette Allonby(GSK Global Scientific Director)
Åä·Ð 05¿ù 19ÀÏ ÄÁÆÛ·±½ºÈ¦ 17:45~17:50 discussion ( )